Background: Early initiation of EPA treatment in combination with a statin within 24 h after percutaneous coronary intervention (PCI) in patients with acute myocardial infarction (MI) reduces inflammation and ventricular arrhythmia compared with statin monotherapy; however, the impact of early initiation of EPA treatment on cardiovascular events is unclear. We determined whether early eicosapentaenoic acid (EPA) treatment in patients with acute coronary syndrome (ACS) reduces adverse cardiovascular events. Methods: This prospective, open-label, blind end point-randomized trial consisted of 241 patients with ACS. Patients were randomly assigned to receive pitavastatin (2 mg/day) with or without 1800 mg/day of EPA initiated within 24 h after PCI. The primary endpoint was defined as cardiovascular events occurring within 1 year, including death from a cardiovascular cause, nonfatal stroke, nonfatal MI and revascularization. Results: The mean EPA/arachidonic acid ratio at follow-up was 0.40 in the control group and 1.15 in the EPA group. A primary endpoint event occurred in 11 patients (9.2%) in the EPA group and 24 patients (20.2%) in the control group (absolute risk reduction, 11.0%; hazard ratio, 0.42; 95% confidence interval, 0.21 to 0.87; P = 0.02). Notably, death from a cardiovascular cause at 1 year was significantly lower in the EPA group than in the control group (0.8% vs. 4.2%, P = 0.04). Conclusions: Early initiation of treatment with EPA combined with statin after successful primary PCI reduced cardiovascular events after ACS.
Introduction
Lowering low-density lipoprotein cholesterol (LDL-C) levels by statins reduces cardiovascular events after acute coronary syndrome (ACS) [1] [2] [3] . In addition, the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study demonstrated that early treatment with atorvastatin initiated 24-96 h after ACS reduced recurrent ischemic events [4] . Thus, early initiation of treatment with statins after ACS is commonly accepted in clinical practice. Although aggressive treatment with statins enables attainment of targeted LDL-C levels, cardiovascular events after ACS is still prevalent [5, 6] . Among putative clinical therapies guarding against residual cardiovascular risks, an increased intake of omega-3 polyunsaturated fatty acids (PUFAs) including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) has been reported to protect against mortality after acute myocardial infarction (MI) [7] [8] [9] .
Ingestion of omega-3 PUFAs including EPA and DHA may attenuate the inflammatory response after MI through multiple mechanisms. Omega-3 PUFAs are readily incorporated into lipid membranes and modify cellular signaling, leading to the disruption of lipid raft-related pro-inflammatory signaling [10] . In addition, the conversion of omega-3 PUFAs into oxygenated bioactive derivatives such as resolvins and protectins promotes the resolution of inflammation [11] [12] [13] [14] . Recent preclinical data have indicated that an acute inflammatory response after MI accelerates systemic atherosclerosis [15] [16] [17] . These results suggest that omega-3 PUFAs could reduce the intensity of the inflammatory response, which then influences clinical outcome after ACS.
We have reported that early initiation of EPA treatment in patients with acute MI reduced the inflammatory response as assayed by highsensitivity C-reactive protein (CRP) on days 3 and 4 [18] . However, the impact of early EPA treatment after ACS on remote-stage clinical outcomes remains unknown. The aim of this study was to investigate whether early initiation of EPA treatment combined with a statin started within 24 h after successful primary percutaneous coronary intervention (PCI) reduced cardiovascular events compared with statin monotherapy in patients after ACS.
Methods

Study design
This study consisted of a prospective, single-center randomized open-labeled trial (Fig. 1) . The study protocol was approved by the ethics committee of Kagawa Prefectural Central Hospital, and written informed consent was obtained from all patients.
Study population
Between November 2010 and March 2014, 329 consecutive ACS patients treated with PCI were eligible to participate as part of the study population (Fig. 2) . ACS was diagnosed according to the American College of Cardiology/American Heart Association 2007 guideline; recentonset chest pain, associated with ST segment and/or negative T wave electrocardiogram (ECG) changes and/or positive cardiac enzymes (creatine kinase or troponin T) [19] . Key exclusion criteria were cardiogenic shock, severe renal insufficiency requiring dialysis, cardiopulmonary arrest, emergent coronary artery bypass, failure of PCI, and expected prognosis less than 1 year because of cancer. Among ACS patients who enrolled in this study, 115 patients with acute myocardial patients were overlapped with our previous study, which evaluated composite events, including cardiac death, stroke, re-infarction, ventricular arrhythmias, and paroxysmal atrial fibrillation within 1 month after PCI. [18] 2.3. Acute-stage treatment and study protocol Before PCI, patients received 200 mg aspirin and 300 mg clopidogrel. PCI was performed with conventional techniques by the femoral or radial approach. Intravenous heparin (10,000 IU) was administered after arterial access was obtained to achieve an activated clotting time of N200 s. Intravenous heparin was continued for 48 h after angioplasty, followed by stent deployment. Post-procedural antithrombotic therapy consisted of 100 mg aspirin daily and 75 mg clopidogrel daily. No patients received glycoprotein inhibitors during the study period.
After PCI, the patients were randomly assigned at a 1:1 ratio to two groups: patients in one group received pitavastatin at a dose of 2 mg plus EPA, which is highly (N 98%) purified EPA ethyl ester (ethyl allcis-5,8,11,14,17-icosapentaenoate), at a dose of 1800 mg (EPA group); those in the other received pitavastatin alone at a dose of 2 mg (control group). Group placement was determined by a research technician according to a computer-generated randomization plan that included stratification by gender and acute MI or unstable angina pectoris. Drugs were started within 24 h after PCI and were continued for at least 52 weeks. We checked the condition of each patient at 1, 3, 6, 9, and 12 months after the initiation of therapy. Laboratory examinations were performed for each patient at admission and 6-9 months after the initiation of therapy.
End points
The primary composite end point consisted of death from a cardiovascular cause, or nonfatal MI, nonfatal stroke, coronary revascularization for new lesions with either PCI or coronary artery bypass graft (CABG). We assessed the first occurrence of one of these events starting from the time of randomization. The secondary composite end point consisted of either a primary end point or hospitalization for heart failure after starting study drugs. Non-fatal acute MI was defined as having at least two of the following: chest pain of typical intensity and duration; ST segment elevation or depression of ≥1 mm in any limb lead of the ECG, of ≥2 mm in any precordial lead, or both; or at least a doubling of necrosis enzyme levels. Diagnosis of non-fatal stroke required unequivocal signs or symptoms of remaining neurological deficit, with sudden onset and a duration of N 24 h.
Data collection
Serum lipids-total cholesterol, HDL-cholesterol (HDL-C), and triglyceride-were measured using an autoanalyzer and routine methods. LDL-C levels were calculated using Friedewald's equation. Concentrations of EPA and DHA were measured on admission (quantification by SRL Company, Tokyo, Japan). Data regarding primary and secondary outcomes were collected from clinical charts, and diagnoses were confirmed by an investigator (M.I.), who was blind to treatment allocation.
Statistical analysis
We assumed that the prevalence of the primary outcomes would be reduced from 15% to 5% by EPA treatment. Regarding incidence of the primary outcomes, the MIRACL study has reported that the incidence of primary outcomes including defined as death, nonfatal acute myocardial infarction, cardiac arrest with resuscitation, or recurrent symptomatic myocardial ischemia with objective evidence and requiring emergency rehospitalization was 15% in the in the atorvastatin group. In addition, regarding the reduction of outcomes with EPA treatment, our previous study showed that early EPA treatment after PCI in acute myocardial infarction (AMI) patients reduced cardiac death, stroke, reinfarction, ventricular arrhythmias, and paroxysmal atrial fibrillation within 1 month from 29% to 11%; therefore, to ensure statistical significance in the detection of reduction within this range (power 80%, α = 0.05), 322 patients were recruited into the study. Sample size was based on anticipated event rates at 1 year of 15% in the control arm [20] . Our previous study showed that early EPA treatment after PCI in AMI patients reduced composite events by one-third [18] . All data were tested for the normal distribution with the KolmogorovSmirnov test. Data that conformed to a normal distribution are summarized as the mean ± standard deviation; those that did not are shown as the median and the first and third quartile. Continuous variables were compared using a paired or unpaired Student's t-test or MannWhitney U-test, as appropriate. Estimates of the hazard ratios (HRs) and associated 95% confidence intervals (CIs) in comparing control and EPA groups were obtained with the use of the Cox proportionalhazards model. Changes in lipid parameters between the two groups were compared using a repeated analysis of variance (ANOVA). A pvalue of b 0.05 was considered statistically significant. Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL). Fig. 2 shows the trial profile. From the initial 329 patients with ACS, 57 patients were excluded. From the remaining 272 patients undergoing emergent PCI, 29 patients refused consent and 2 had failed PCI. Of the 241 patients who were enrolled and randomly assigned to the EPA and control groups (120 and 121, respectively), 1 patient from the EPA group was excluded because of drug eruption, and 2 patients from the control group were excluded because they did not return for a follow-up, leaving a total of 119 patients in each group. Table 1 shows the baseline characteristics for the patients and the coronary anatomy and angiographic results of the two groups, which were comparable in age, gender, prevalence of diabetes, hypertension, dyslipidemia, and acute MI. In those patients with acute MI (control, n = 77; EPA, n = 80), the two groups were also comparable in Killip class on admission, culprit vessel, onset-to-reperfusion, and final thrombolysis in MI (TIMI) flow grade.
Results
Study population
At the time of randomization, there was no significant difference in the ratio of EPA to arachidonic acid (AA) or the lipid profile before PCI ( Table 1 ). The reduction in LDL-C was comparable between the two groups (p = 0.21 by repeated ANOVA), and the final mean LDL-C levels were 120.8 mg/dl and 117.7 mg/dl in the control and EPA groups, respectively (Fig. 3) . Triglyceride did not change during the study period and remained comparable between the two groups (p = 0.61). Final mean triglyceride levels were 138.8 mg/dl and 120.8 mg/dl in the control and EPA groups, respectively. The plasma EPA concentration in the EPA group (162.8 μg/ml) was significantly higher than that of the control group (65.5 μg/ml) during follow-up (p b 0.001). Similarly, the EPA/AA ratio of the EPA group increased more than that of the control group, and this difference was maintained during follow-up (final ratios, 1.15 vs. 0.39, respectively; p b 0.001).
Primary and secondary outcomes
Kaplan-Meier event rates for the primary end point of cardiovascular death, MI, stroke, or coronary revascularization at 1 year were 9.2% in the EPA group and 20.2% in the control group (absolute risk reduction, 11.0%; HR, 0.42; 95% CI, 0.21-087; P = 0.02) (Fig. 4A, Table 2 ). In terms of non-cardiovascular death, 4 patients in the control group died due to pneumonia, (n = 3) and traffic accident (n = 1) and one patients in the EPA group died due to pneumonia (n = 1). The rate of the secondary end point of cardiovascular death, MI, stroke, coronary revascularization, or hospitalization for heart failure was significantly lower, by 10.9%, in the EPA group than in the control group (HR, 0.90; 95% CI, 0.26-0.98; p = 0.04) (Fig. 4B and Table 2 ). Notably, death from a cardiovascular cause at 1 year was significantly lower in the EPA group than in the control group (4.2% vs. 0.8%; absolute risk reduction, 5.9%; HR, 0.22; 95% CI, 0.47-0.99; p = 0.04) ( Table 2 ).
Discussion
After ACS, early initiation of a combined EPA and statin treatment within 24 h after successful primary PCI resulted in a significantly lower risk of cardiovascular events than that obtained with statin monotherapy. The reduction of primary outcomes was mainly due to a decrease in death from a cardiovascular cause. This is the first study to assess the additive effect of 1800 mg/day of EPA treatment combined with a statin on cardiovascular events after ACS compared with the outcome from therapy with a statin alone.
Our study is different from those reported previously in several aspects. First, EPA treatment was started within 24 h after primary PCI. Previous randomized clinical trials reported the usefulness of omega-3 PUFAs for the prevention of secondary adverse cardiovascular events in post-MI patients. Results from the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) prevention trial have shown that treatment with EPA + DHA (1 g/day) lowered sudden cardiac death in patients after MI [7] . In the GISSI prevention trial, omega-3 PUFA was started within 3 months after MI. In the Japan EPA Lipid Intervention Study (JELIS), hypercholesterolemic patients with or without a history of cardiovascular events were administered EPA (1.8 g/day) in combination with a mild statin; the results showed a reduction in cardiovascular events for all participants [20] . In our study, EPA treatment was initiated within 24 h after primary PCI, which is earlier than in the MIRACL Study that reported the benefits of early treatment with atorvastatin initiated 24-96 h after ACS [4] . In our pilot randomized study, the EPA/AA ratio was increased 1 day after intake of EPA (1800 mg/day) and was significantly higher on the third day in EPA-treated subjects as compared with levels in control subjects (p b 0.05, data not shown). Thus, the early initiation of EPA treatment increased plasma EPA concentration within a few days. Second, all patients included in this study underwent primary PCI successfully. In the GISSI prevention trial, patients treated by thrombolysis were included. Third, pitavastatin was administered to all patients regardless of EPA treatment. A substudy of JELIS showed EPA is effective for prevention of secondary coronary artery disease, especially in individuals with prior MI [21] . However, in JELIS, a mild statin was administered with EPA treatment. Taken together, these differences strengthen our finding that early initiation of EPA treatment is beneficial in patients undergoing primary PCI and receiving a statin after ACS.
There are several possible mechanisms for the observed relationship between EPA treatment and the reduction of cardiovascular events after ACS. Ventricular arrhythmia after primary PCI in patients with acute MI is reported to be associated with an increased 90-day mortality [22] . We have reported that early EPA treatment after primary PCI reduced the incidence of ventricular arrhythmias in the acute stage of MI [18] . Thus, one explanation is that the anti-arrhythmic effect of EPA treatment early after PCI could contribute to the better prognosis at 1 year after ACS that was noted in this study. Another possibility is the antiinflammatory effect of EPA. Pietila et al. reported that high serum CRP concentrations in acute MI patients treated with thrombolytic drugs predicted increased mortality up to 6 months [23] . Omega-3 PUFAs attenuates the inflammatory response through multiple mechanisms. Omega-3 PUFAs reduce the content of AA in membrane phospholipids, resulting in a competitive decrease in the production of AA-derived proinflammatory mediators [24] . In addition, the conversion of omega-3 PUFAs into oxygenated bioactive derivatives such as resolvins and protectins reduces inflammation [11] [12] [13] [14] . Also, the combination of EPA and aspirin may enhance the production of resolvins. For the generation of resolvin E1, aspirin acetylates cyclooxygenase-2 (COX2) in vascular endothelial cells and generates 18R-hydroperoxyeicosapentaenoic acid (18R-HPEPE), which is further converted via 5-lipoxygenase and additional enzymatic reactions in leukocytes to form resolvin E1 [25] . Both the anti-arrhythmic and antiinflammatory effects of EPA in the early phase after ACS may be beneficial for long-term outcomes.
Several experimental studies have shown the anti-atherosclerotic effects of EPA [26, 27] . Oral EPA supplementation reduces atherosclerotic lesions in ApoE-deficient mice [26] by inhibiting endothelial activation. This result was further supported by experimental results showing that oral EPA administration over a 3-month period inhibited monocyte adhesion to endothelial cells in vitro and decreased plasma concentrations of soluble intercellular adhesion molecule 1 [28] . In a clinical study, EPA treatment decreased carotid intima-media thickness (IMT) in patients with hypertriglyceridemia [29] . Nishio et al. reported that in patients undergoing PCI for ACS, treatment with EPA plus rosuvastatin for 9 months produced a large increase in fibrous cap thickness as determined with optical coherence tomography [30] . Thus, EPA treatment prevents or stabilizes coronary atherosclerotic plaques, which reduces the risk of acute plaque rupture and ACS.
Residual cardiovascular risks remain in many patients despite statin therapy, even at high doses. The residual risks include high levels of triglyceride, very-low-density lipoprotein, and remnant-like lipoparticle cholesterol (RLP-C). Omega-3 PUFAs have beneficial effects through the reduction in the levels of these triglyceride-rich lipoproteins [31] [32] [33] , suggesting the potential of omega-3 PUFAs as an add-on therapy to statins. In addition, The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults [34] questioned add-on therapy to statins. A recent study showed that combinatorial statin therapy after ACS reduced cardiovascular outcomes and suggested lowering LDL-C to levels below previous targets [35] . Thus, the concept that lower LDL-C is beneficial is still important. In this respect, omega-3 PUFAs containing DHA may raise LDL-C [36, 37] . Highly purified EPA reduces atherogenic triglyceriderich lipoproteins but does not raise LDL-C [30] . Our study supports the proposition that supplementation with pure EPA may reduce cardiovascular events in statin-treated patients.
Limitations
There are some limitations in the present study. First, this is a singlecenter trial and the number of patients was relatively small, although the final number in the study population did reach the predetermined target. Second, this study was not of a double-blind design. Although the investigator in charge of data collection and diagnosis was blind to treatment allocation, patients and physicians were not. Third, as clinical outcomes were followed only up to 1 year, it remains unknown whether this timing of initiation and dose of EPA is optimal to longterm prognosis in patients after ACS. To establish the clinical utility of EPA treatment in patients with ACS, a multicenter randomized trial with a larger population is warranted.
Conclusion
Early initiation of EPA combined with statin treatment started within 24 h after successful primary PCI resulted in reduced cardiovascular events; thus, EPA treatment constitutes a promising therapy after primary PCI in patients with ACS.
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